Similarly, ACC patients with low BRD2, BRD3, and BRD4 expressions had longer disease-free survival than those with high BRD2 (P = 0.0042) (Figure 1E), BRD3 (P = 0.00012) (Figure 1G), and BRD4 expressions (P = 3.9e-5) (Figure 1I). This evidence concerns the gene BRD2 and adrenal cortex carcinoma.